Immunic Inc (IMUX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

AM KLOPFERSPITZ 19 MARTINSRIED, GERMANY 82152

Vital Therapies, Inc. develops and discovers cell based therapies. The Company designs and produces medical cartridges to stabilize liver function in patients. Vital Therapies serves customers worldwide.

Data as of 2020-11-22
Market Cap389.712 Million Shares Outstanding20.718 Million Avg 30-day Volume250.424 Thousand
P/E Ratio-6.4 Dividend Yield EPS-2.95
Price/Sales Price cash flow ratio Price free cash flow ratio-10.1
Book Value7.86 Price to Tangible Book3.0 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.123599
BETA2.24598 52-week High/Low23.39 / 4.19 Stddev0.269215
View SEC Filings from IMUX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 66 54 22.22% 20 (1.31%) 15 (0.97%) 33.33%
13F shares: 8.416 Million 4.207 Million 100.06% 4.657 Million 2.429 Million 91.74%
% Ownership 40.62 28.1035 44.54% 22.4769 16.2254 38.53%
New Positions: 26 30 -13.33% 11 11 0.0%
Increased Positions 25 12 108.33% 6 2 200.0%
Closed Positions 11 2 450.0% 6 1 500.0%
Reduced Positions 8 4 100.0% 2
Total Calls 111.535 Thousand 55.8 Thousand 99.88% 25.3 Thousand
Total Puts 31.923 Thousand 0
PUT/CALL Ratio 0.29 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IMUX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMUX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NASH DUANE EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2020-10-22 3

WHALEY GLENN PFO AND PAO

  • Officer
1,000 2020-08-10 5

GROEPPEL MANFRED CHIEF OPERATING OFFICER

  • Officer
278,830 2020-07-20 2

VITT DANIEL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
362,877 2020-07-20 2

VAN DEN BOSSCHE JAN

  • Director
0 2020-07-02 1

NEERMANN JOERG

  • Director
0 2020-07-02 1

HOWSON TAMAR D

  • Director
0 2020-07-02 1

PHILLIPS BARCLAY A

  • Director
0 2020-07-02 1

OSSIPOW VINCENT

  • Director
0 2019-07-22 0

PATEL SANJAY S CHIEF FINANCIAL OFFICER

  • Officer
0 2019-07-22 0

GLOBAL LIFE BIOVENTURE V SARL

OMEGA FUND V, L.P.

OMEGA FUND V GP, L.P.

OMEGA FUND V GP MANAGER, LTD.

LIM RICHARD J.

STAMPACCHIA OTELLO

NESSI CLAUDIO

PASTER ANNE-MARI

  • 10% Owner
1,371,494 2019-04-12 0

LSP V COOPERATIEVE U.A.

LSP V MANAGEMENT B.V.

  • 10% Owner
2,162,782 2019-04-12 0

FUND N.V.

  • 10% Owner
1,371,494 2019-04-12 0

DUNN JOHN MICHAEL GENERAL COUNSEL AND SECRETARY

  • Officer
0 2019-01-11 0

SWANSON MICHAEL V. CHIEF FINANCIAL OFFICER, EVP

  • Officer
0 2019-01-11 0

ASHLEY ROBERT A. CHIEF SCIENTIFIC OFFICER, EVP

  • Officer
0 2019-01-11 0

COX RUSSELL J. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2019-01-11 0

HALPERIN ERROL R.

  • Director
0 2018-09-25 0

BIENAIME JEAN JACQUES

  • Director
18,500 2018-09-24 0

GODSHALL DOUGLAS EVAN

  • Director
0 2018-09-19 0

SATTER MUNEER A

  • Director
  • 10% Owner
0 2018-09-13 0

HASNAIN FAHEEM

  • Director
8,000 2018-09-13 0

COHEN CHERYL

  • Director
0 2018-09-12 0

STERN ARON CHIEF ADMINISTRATIVE OFFICER

  • Officer
0 2018-07-01 0

HENRY ANDREW VP, CLINICAL OPERATIONS

  • Officer
0 2018-06-09 0

MURAWSKI RICHARD M VICE PRESIDENT, MANUFACTURING

  • Officer
0 2018-06-09 0

SEARS LOWELL

  • Director
0 2018-05-23 0

MILLIS J. MICHAEL

  • Director
0 2018-05-23 0

WINTERS TERENCE E. CO-CHAIRMAN AND CEO

  • Officer
  • Director
314,930 2017-06-14 0

CROXFORD PHILIP M

  • Director
0 2017-05-23 0

STEER RANDOLPH C

  • Director
0 2017-05-23 0

LOEWEN ANDREA SEE REMARKS

  • Officer
0 2016-05-13 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

NASH DUANE - Director - Officer EXECUTIVE CHAIRMAN

2020-10-22 19:40:50 -0400 2020-10-22 A 120,000 a 120,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments